Alzheimer's Disease

Neurology
0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
1 program
Lecanemab treatment groupN/A1 trial
Active Trials
NCT06871839Recruiting120Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2025
2026
EisaiLecanemab treatment group

Clinical Trials (1)

Total enrollment: 120 patients across 1 trials

NCT06871839EisaiLecanemab treatment group

The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease

Start: Mar 2025Est. completion: Dec 2026120 patients
N/ARecruiting

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 120 patients
1 companies competing in this space